Salute e Benessere
UNION therapeutics announces presentation of preliminary data from Phase 2a investigator-initiated study with orismilast in ulcerative colitis at the 20th ECCO Congress
Poster title: Orismilast for the Treatment of Moderate to Severe Ulcerative Colitis: A phase 2a, open-label, single-arm explorative clinical study
Authors: Trine Velte Honoré, Flemming Bendtsen , Jakob Seidelin, Johan Burisch
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that causes inflammation and ulcers (sores) in the lower digestive tract, i.e. colon and rectum. More than 1.8 million patients are diagnosed with UC in the US, Japan and EU5 and the incidence of UC is increasing worldwide . Despite the treatment options available today, an unmet medical need for safe oral treatments with improved efficacy remains. UC is a disease that can be in remission (less active) for longer periods of time and then suddenly flare (termed "relapse"). During periods of relapse, patients experience a significant impact on their everyday lives, experiencing symptoms such as bloody stool, diarrhea, fecal incontinence, increased frequency of bowel movements (urgency), fatigue, and abdominal pain (cramps).
Depending on the severity of UC and patient preferences, the treatment is tailored accordingly. Patients with mild UC are often treated with mild anti-inflammatory medication, taken orally or rectally, such as aminosalicylates, corticosteroids or immunomodulators. Patients with moderate to severe UC are often treated with immunosuppressants, biologics or a combination of such treatments. Overall, treatments aim to induce a rapid clinical response and maintain remission, ideally healing the ulcers and preventing long-term disability.
UNION is developing orismilast, a high-potency PDE4 inhibitor targeting the PDE4B/D subtypes linked to inflammation, demonstrating potent inhibition of Th1, Th2 and Th17 pathways. It operates early in the inflammation cascade, inducing a broad range of anti-inflammatory effects across multiple cytokines involved in many dermatological and immunological diseases.
Orismilast holds the potential to become a safe and efficacious oral treatment for several immunological diseases , and UNION is currently developing oral orismilast for the treatment of hidradenitis suppurativa (HS).
The FDA has cleared UNION's Investigational New Drug (IND) application for oral orismilast and granted Fast Track designation for oral orismilast for the treatment of moderate to severe HS as well as for the treatment of moderate to severe atopic dermatitis.
Morten Boesen , Chief Financial Officer, UNION therapeutics A/S
+45 2381 5487
morten.boesen@uniontherapeutics.com
UNION therapeutics is a privately held, clinical stage, pharmaceutical development company focused on immunology. UNION is headquartered in Hellerup, Denmark , and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching multiple marketed drugs. Read more at www.uniontherapeutics.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/union-therapeutics/r/union-therapeutics-announces-presentation-of-preliminary-data-from-phase-2a-investigator-initiated-s,c4109415
View original content:https://www.prnewswire.co.uk/news-releases/union-therapeutics-announces-presentation-of-preliminary-data-from-phase-2a-investigator-initiated-study-with-orismilast-in-ulcerative-colitis-at-the-20th-ecco-congress-302382223.html